Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2019 Symposium /
RET inhibition in RET aberrant cancers

23rd - 24th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.07.19
Views: 328
Rating:

Dr Vivek Subbiah - University of Texas MD Anderson Cancer Center, Houston, USA

Dr Vivek Subbiah speaks to ecancer at the WIN 2019 Symposium in Paris about RET inhibition in RET aberrant cancers.

He explains that RET is an oncogenic driver seen in multiple cancers, most commonly lung cancers.

Dr Subbiah discusses various RET inhibitors with an important one being including BLU-667 which, following study, has been granted two US breakthrough designations.
 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation